July 1, 2019, Pharmacy Times 

Officials with the U.S. Food and Drug Administration have approved bevacizumab-bvzr (Zirabev, Pfizer), a biosimilar to bevacizumab (Avastin), for the treatment of five types of cancer, according to a press release. Bevacizumab-bvzr is indicated for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer. 

Read more.